Paliperidone for Irritability in Autistic Disorder

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision. Washington (DC): American Psychiatric Association, 2000.

Davidson M , Emsley R , Kramer M , Ford L , Pan G , Lim P , Eerdekens M . Efficacy, safety, and early response of paliperidone extended-release tablets: Results of a 6-week, randomized, placebo-controlled study. Schizophr Res, 93:117–130. 2007.

Ereshefsky L , Mascarenas CA . Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry, 64:18–23. 2003.

Findling RL , Maxwell K , Wiznitzer M . An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull, 33:155–159. 1997.

Guy W . ECDEU assessment manual for psychopharmacology (NIMH Publication No. 76-338) Washington (DC): DHEW, NIMH, 1976.

Kane J , Canas F , Kramer M , Ford L , Gassmann-Mayer C , Lim P , Eerdekens M . Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophr Res, 90:147–164. 2007.

Karlsson P , Dencker E , Nyberg S , Mannaert E , Boom S , Talluri K , Rossenu S , Eriksson B , Eerdekens M , Farde L . Pharmacokinetics, D2, serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects. Eur Neuropsychopharmacol, 15,Suppl 3:S386. 2005.

Lord C , Rutter M , Le Couteur AM . Autism diagnostic interview-revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord, 27:659–685. 1994.

Marder SR , Kramer M , Ford L , Eerdekens E , Lim P , Eerdekens M , Lowy A . Efficacy and safety of paliperidone extended-release tablets: Results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry, 62:1363–1370. 2007.

Masi G , Cosenza A , Mucci M , Brovedani P . Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry, 40:1206–1214. 2001.

McDougle CJ , Holmes JP , Bronson MR , Anderson GM , Volkmar FR , Price LH , Cohen DJ . Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective open-label investigation. J Am Acad Child Adolesc Psychiatry, 36:685–693. 1997.

McDougle CJ , Scahill L , Aman MG , McCracken JT , Tierney E , Davies M , Arnold LE , Posey DJ , Martin A , Ghuman JK , Shah B , Chuang SZ , Swiezy NB , Gonzalez NM , Hollway J , Koenig K , McGough JJ , Ritz L , Vitiello B . Risperidone for the core symptom domains of autism: Results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology. Am J Psychiatry, 162:1142–1148. 2005.

Meltzer HY , Bobo WV , Nuamah F , Lane R , Hough D , Kramer M , Eerdekens M . Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: Pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry, 69:817–829. 2008.

Nicolson R , Awad G , Sloman L . An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry, 37:372–376. 1998.

Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med, 347:314–321. 2002.

Shea S , Turgay A , Carroll A , Schulz M , Orlik H , Smith I , Dunber F . Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114:e634–641. 2004.

Schooler N , Gharabawi G , Bossie C et al. A virtual comparison of paliperidone ER and oral risperidone in patients with schizophrenia. Chicago (Illinois): Collegium Internationale Neuro-Psychopharmacologicum, 2006.

Stigler KA , McDougle CJ . Pharmacotherapy of irritability in pervasive developmental disorders. Child Adolesc Psychiatric Clin N Am, 17:739–752. 2008.

Vermeir M , Boom S , Naessens I , Talluri K , Eerdekens M . Absorption, metabolism and excretion of a single oral dose of 14C-paliperidone 1 mg in healthy subjects. Eur Neuropsychopharmacol, 15,Suppl 3:S191–S192. 2005.